Scientific interpretation of the mechanism and efficacy of Trelagliptin as an antidiabetic drug
Trelagliptin (Trelagliptin) is a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) and is a type of oral hypoglycemic drug. It is mainly used to treat type 2 diabetes and help patients control blood sugar fluctuations by regulating blood sugar levels. The advantage of trotagliptin is that it only needs to be taken once a day, which is more convenient. At the same time, there are no strict restrictions on meal times, making it suitable for patients with long-term blood sugar management.
The main mechanism of action of trolagliptin is to inhibit DPP-4 enzyme activity, thereby prolonging the half-life of incretins (GLP-1 and GIP). Incretins can promote insulin secretion from pancreatic beta cells while inhibiting glucagon secretion. Through this two-way regulation, trotagliptin can enhance insulin secretion when blood sugar rises, but will not cause hypoglycemia when blood sugar is normal or low, thereby achieving a safe and effective blood sugar-lowering effect.

Clinical studies have shown that trotagliptin can significantly reduce postprandial and fasting blood glucose levels when used alone or in combination with other antidiabetic drugs. Long-term use can improve glycosylated hemoglobin (HbA1c) levels, reduce cardiovascular risk, and is well tolerated by patients. Compared with traditional sulfonylureas, trotagliptin has a lower risk of hypoglycemia and does not cause significant weight gain, making it suitable for patients with high weight management needs.
Trelagliptin is generally well tolerated, and common adverse reactions include mild upper respiratory tract infection, headache, or gastrointestinal discomfort. In patients with renal impairment, the dose may need to be adjusted, but frequent monitoring of liver function is usually not required. In clinical application, trotagliptin can be used as a single drug or combination therapy, especially for patients with type 2 diabetes who require long-term and stable blood sugar control, providing a safe and convenient solution for blood sugar management.
Reference link:https://www.drugs.com
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)